Olatoyosi Odenike to Pyrazoles
This is a "connection" page, showing publications Olatoyosi Odenike has written about Pyrazoles.
Connection Strength
0.558
-
Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase. Blood Adv. 2020 10 27; 4(20):5246-5256.
Score: 0.176
-
Allo-SCT for myelofibrosis: reversing the chronic phase in the JAK inhibitor era? Bone Marrow Transplant. 2015 May; 50(5):628-36.
Score: 0.118
-
Ruxolitinib: long-term management of patients with myelofibrosis and future directions in the treatment of myeloproliferative neoplasms. Curr Hematol Malig Rep. 2014 Dec; 9(4):350-9.
Score: 0.117
-
Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts. J Hematol Oncol. 2013 Oct 29; 6(1):81.
Score: 0.108
-
Oral MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Patients With Acute Myeloid Leukemia With RAS Mutations: A Phase II Study. Clin Lymphoma Myeloma Leuk. 2019 07; 19(7):431-440.e13.
Score: 0.039